PT - JOURNAL ARTICLE AU - Susan Prendeville AU - Theodorus H van der Kwast TI - Lymph node staging in prostate cancer: perspective for the pathologist AID - 10.1136/jclinpath-2016-203643 DP - 2016 Dec 01 TA - Journal of Clinical Pathology PG - 1039--1045 VI - 69 IP - 12 4099 - http://jcp.bmj.com/content/69/12/1039.short 4100 - http://jcp.bmj.com/content/69/12/1039.full SO - J Clin Pathol2016 Dec 01; 69 AB - Pelvic lymph node dissection (PLND) currently represents the gold standard method for nodal staging in the setting of localised prostate cancer and may also have a therapeutic benefit in certain patients. The histopathological evaluation of PLND specimens plays a critical role in accurate lymph node staging, however there is currently a lack of consensus regarding the optimum approach and no quality parameters are in place. In addition, there are no guidelines as to the handling of less commonly encountered nodal specimens such as those identified within the anterior fat pad. This summary provides an overview of pertinent issues regarding lymph node staging in prostate cancer, with a focus on the histopathological evaluation of resected nodal specimens. We hope that this review will further the discussion on how to achieve a more standardised approach to the processing and reporting of PLND specimens in the setting of prostate cancer.